Literature DB >> 28360579

The Face of Chronic Migraine Which Has Started to be Clarified.

Zeynep Aydin Özemir1, Betül Baykan2.   

Abstract

Recently, information about migraine which is generally characterized with attacks has gradually increased. In some patients with migraine, progression may be observed such that the frequency and time of the attacks are increased and an attack lasts for days. This condition is called chronic migraine (CM). According to the last classification, chronic migraine is defined as headache which occurs 15 days a month or more frequently at least 8 of which show the characteristic properties of migraine or response to migraine-specific treatment. The diagnostic cirteria of chronic migraine, its differences from other chronic daily headaches and the question if it is a migraine form with a high frequency which transforms from episodic migraine or a completely different pathophysiological picture are still contradictory. Clarifying these issues is possible with clinical studies as well as increasing the studies directed to investigate the pathophysiological mechanisms.

Entities:  

Keywords:  Chronic migraine; chronic daily headache; headache

Year:  2013        PMID: 28360579      PMCID: PMC5353073          DOI: 10.4274/npa.y7244

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.339


  46 in total

Review 1.  Risk factors for headache chronification.

Authors:  Ann I Scher; Lynn A Midgette; Richard B Lipton
Journal:  Headache       Date:  2008-01       Impact factor: 5.887

2.  New appendix criteria open for a broader concept of chronic migraine.

Authors:  J Olesen; M-G Bousser; H-C Diener; D Dodick; M First; P J Goadsby; H Göbel; M J A Lainez; J W Lance; R B Lipton; G Nappi; F Sakai; J Schoenen; S D Silberstein; T J Steiner
Journal:  Cephalalgia       Date:  2006-06       Impact factor: 6.292

3.  Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.

Authors:  Stephen D Silberstein; Stuart R Stark; Sylvia M Lucas; Suzanne N Christie; Ronald E Degryse; Catherine C Turkel
Journal:  Mayo Clin Proc       Date:  2005-09       Impact factor: 7.616

4.  Efficacy of gabapentin in migraine prophylaxis.

Authors:  N T Mathew; A Rapoport; J Saper; L Magnus; J Klapper; N Ramadan; B Stacey; S Tepper
Journal:  Headache       Date:  2001-02       Impact factor: 5.887

5.  Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study.

Authors:  Joel R Saper; Alvin E Lake; Deborah T Cantrell; Paul K Winner; Jeffery R White
Journal:  Headache       Date:  2002-06       Impact factor: 5.887

Review 6.  Evidence for antinociceptive activity of botulinum toxin type A in pain management.

Authors:  K Roger Aoki
Journal:  Headache       Date:  2003 Jul-Aug       Impact factor: 5.887

7.  Migraine as a risk factor for subclinical brain lesions.

Authors:  Mark C Kruit; Mark A van Buchem; Paul A M Hofman; Jacobus T N Bakkers; Gisela M Terwindt; Michel D Ferrari; Lenore J Launer
Journal:  JAMA       Date:  2004-01-28       Impact factor: 56.272

8.  Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment.

Authors:  Marcelo E Bigal; Daniel Serrano; Michael Reed; Richard B Lipton
Journal:  Neurology       Date:  2008-08-19       Impact factor: 9.910

9.  A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.

Authors:  Ninan T Mathew; Sayyed Farhan A Jaffri
Journal:  Headache       Date:  2009 Nov-Dec       Impact factor: 5.887

10.  Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers.

Authors:  D C Buse; A Manack; D Serrano; C Turkel; R B Lipton
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-02-17       Impact factor: 10.154

View more
  3 in total

1.  Evaluation of OnabotulinumtoxinA Treatment in Patients with Concomitant Chronic Migraine and Temporomandibular Disorders.

Authors:  Gülşen Kocaman; Neşe Kahraman; Banu Gürkan Köseoğlu; Başar Bilgiç; Zeliha Matur; Mustafa Ertaş; Yeşim Gülşen; Betül Baykan Baykal
Journal:  Noro Psikiyatr Ars       Date:  2018-07-06       Impact factor: 1.339

2.  Association between epilepsy and headache.

Authors:  Aytül Mutlu
Journal:  Neurol Sci       Date:  2018-09-12       Impact factor: 3.307

3.  Different mean thickness implicates involvement of the cortex in migraine.

Authors:  Zhi-Bo Yu; Jing Peng; Yan-Bing Lv; Ming Zhao; Bing Xie; Ming-Long Liang; Hai-Tao Li; Zhen-Hua Zhou
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.